Business Wire

Japanese Dietary Supplement: Nichi Glucan, an Immune Booster in Covid-19

17.6.2020 10:19:00 EEST | Business Wire | Press release

Share

A unique Beta 1,3-1,6 Glucan based Japanese health supplement, produced by black yeast, Aureobasidium Pullulans, could strategically help tackle Covid-19 in people with comorbid conditions like diabetes, kidney and heart diseases, as published in Frontiers in Immunology Journal recommending clinical studies (https://www.frontiersin.org/articles/10.3389/fimmu.2020.01548/abstract), for validation. This AFO-202 strain produced “Nichi Glucan” enhanced the immunity by increasing Natural Killer (NK) cells and anti-viral cytokines of healthy people, cancer patients and elderly, in three different studies in Japan. Encouraging outcome of earlier studies inspired us to hypothesize that, benefits of this food supplement in boosting the immunity could help during this pandemic, said Dr. Nobunao Ikewaki, a co-author.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200617005239/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Mechanisms of immune balancing potentials by Nichi Glucan from Japan, that make it worth a clinical study in Covid-19 (Graphic: Business Wire)

Analyzing the intricacies and weakness of immune system in people with comorbid conditions, making them vulnerable to severe complications when infected by SARS-COV-2, scientists say that immune system must protect the body from pathogens like viruses, but shouldn’t over-act causing hyper inflammation leading to cytokine storm ensuing in respiratory failure or complications like stroke. Nichi Glucan having been found to boost protective factors like Cytotoxic T Cells and immunoglobulins, while controlling those lead to hyper inflammation through sFas and Treg cells, balancing as immunomodulator, has potentials worth clinical studies during this global health crisis, they opine.

Unique advantages of this biological response modifier glucan are attributed to its purity, being produced as an exo-polysaccharide and its water solubility. Nichi Glucan is manufactured in a GMP factory in the banks of upstream Niyodo river in Kochi prefecture. "Pristine water of this region is a key ingredient for production, making Nichi Glucan a nature's gift," says Mr. Takashi Onaka, President, Sophy Inc., the manufacturer.

Approved as food additive in 1996 after conforming to all safety norms of Japanese standards, Nichi Glucan isn’t a drug or cure to any illness. However, in the present situation, without vaccines to prevent or drugs to tackle the Covid-19 virus or its complications, it could be tried in studies to confirm efficacy in helping the immunocompromised vulnerable population through immune enhancement, comment the authors. Further research is underway to develop newer versions with higher adhesion for improvised immune stimulation. GN Corporation, the exclusive worldwide exporter, co-applicants to a patent with Sophy Inc., are looking for country-wise partners for further research & distribution (www.nichiglucan.com).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Samuel JK Abraham
GN Corporation
info@gncorporation.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye